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Background. Resection of gliomas located in eloquent
brain areas remains a neurosurgical challenge. The re-
ported incidence of transient or permanent neurological
deficits after microsurgery in eloquent brain ranges
20%–100%, or 0%–47% among contemporary neuro-
surgical series. The aim of this studywas to assess the fea-
sibility of stereotactic brachytherapy (SBT) as a local
treatment alternative to microsurgical resection for pa-
tients with gliomas in highly eloquent areas, located in
the central sulcus region (CSR).
Method. Between1997and2010,60patientswithWorld
Health Organization (WHO) grades II and III gliomas
located in the CSR were treated with SBT (iodine-125
seeds; cumulative therapeutic dose, 50–65 Gy). Follow-
ing SBT, WHO grade III glioma patients additionally re-
ceived percutaneous radiotherapy (median boost dose,
25.2 Gy). We evaluated procedure-related complications,
clinical outcome, and progression-free survival.
Results. Procedure-related mortality was zero. Within 30
days of SBT, 3 patients (5%) had transient neurological
deficits, and 8 patients (13%) had temporarily increased
seizure activity. One patient (1.6%) deteriorated perma-
nently. Space-occupying cysts (6 patients) and radiation
necrosis (1 patient) developed after a median of 38
monthsandrequiredsurgical intervention.Seizureactivity,
rated 12 months following SBT, decreased in 82% of pa-
tients (Engel classes I–III).Medianprogression-free surviv-
alswere62.2+19.7months(grade IIgliomas)and26.1+
17.9 months (grade III gliomas).
Conclusions. Compared with microsurgical resection,
SBTharborsa lowriskofproceduralcomplications, ismin-
imally invasive, andseemstobeaneffective local treatment
option for patients with inoperable, eloquentWHO grade
IIand III gliomas in theCSR.However, thevalueofSBTfor
treatinggliomas still needs tobedetermined inprospective,
randomized studies.
Keywords: central sulcus region, eloquent gliomas,
stereotactic iodine-125 brachytherapy, SBT.
M
icrosurgical resection is considered a critical
therapeutic modality for patients diagnosed
with gliomas, and growing evidence suggests
that patients’ survival correlates with the extent of resec-
tion.1,2 However, these tumors are frequently located in
or involve eloquent brain (eg, sensory-motor or language
areas, basal ganglia, or subcortical pathways),3 limiting
theneurosurgicalattemptofacompleteorgross total resec-
tionof these tumors.4 In this context, contemporaryneuro-
surgical series report transientandpermanentneurological
deficits ranging 20%–100%5,6 and 0%–47%,6,7 respec-
tively, after resections in eloquent brain.
Stereotactic brachytherapy (SBT) with implantation
of iodine-125 (125I) seeds represents a safe and effective
local treatment option for selected patients, including
those with circumscribed tumors located in eloquent
brain.8–10 Histological evaluation within the same oper-
ative session, precise treatment of the tumor, maximal
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sparing of surrounding healthy tissue, minimal rate of
long-term complications, and preservation of the whole
therapeutic spectrum in case of tumor progression (eg, re-
implantation, external beam radiotherapy [EBRT]) are
described hallmarks of SBT.9–11
In the present study, we focused on the application of
SBT for gliomas located in sensory-motor areas, which
are primarily localized at the pre- and postcentral gyrus,
also known as the central sulcus region (CSR).12 We as-
sessed the feasibility of SBT as a local treatment regimen
by evaluating the patient’s clinical and oncological
outcome, and comparedour resultswith those in the liter-
ature reported for microsurgical series in the CSR.
Material and Methods
Indications for SBT
Treatmentwascarriedout according toaprospectivepro-
tocol.9,10 In brief, patients were eligible (i) when tumors
were considered inoperable due to localization in elo-
quentbrain; (ii) for treatmentof residual tumors after sub-
total resection; and/or (iii) with relapse of previously
treated tumors. In addition, a KPS score ≥60 and a well-
circumscribed tumorof≤40 mmwere requested.Tumors
displayingcontrast enhancementwerewell circumscribed
if their calculated size was the same or nearly the same in
contrast enhanced T1- and T2-weighted MRI.11,13
Non-enhancing tumors were defined as well circum-
scribed based exclusively on T2-weightedMRI. An inter-
disciplinary tumor board confirmed every indication.
Either parents or the patients themselves if ≥18 years
old signed informed consent after detailed explanation
of procedure-related risks and agreed that their data
could be used for scientific evaluation.
Selection of Study Population
For thepresent study, all patientswhohadundergoneSBT
for inoperable World Health Organization (WHO)
grades II and III gliomas in the time period 1997–2010
were reviewed; almost 500 patients were identified.
In a second step, preoperative MR images (T1- and
T2-weighted sequences) were reviewed to identify the
tumor location within the CSR. The central sulcus was
used as the anatomical reference, either identified directly
or by the ascending cingulate sulcus visible in the midline
sagittal image to define the pre- and postcentral gyrus
from this point. This analysis was independently per-
formed by 2 investigators with experience in neurosurgi-
cal oncology (M.I.R., S.G.). Only those cases where both
investigators confirmed the tumor location within the
CSR were included in the present study.
Treatment Planning and Surgical Procedure
Surgical procedures were carried out as described previ-
ously.9,10,14,15 In brief, under general anesthesia a modi-
fied Riechert–Mundinger stereotactic frame was fixed
on the patient’s head and an intraoperative stereotactic
CT was performed. Thereafter, CT scans were fused
with preoperative contrast enhanced axial T1- and
T2-weightedMR images. For image fusion and planning
of the trajectory and irradiation treatment, we used spe-
cialized software (STP3,StrykerLeibinger).The radiation
dose prescribed at the target volume surface (median
dose, 50 Gy) was delivered as low-dose irradiation with
an initial dose rate of 0.75 Gy/d. Permanent implants
were used, meaning that the catheters were left in situ
even after the decay of activity. Patients with WHO
grade III gliomas additionally received EBRT (median
boost dose, 25.2 Gy in fractions of 1.8 Gy) during the
first 3 weeks following SBT.16 The rationale for this
treatment protocol was to increase the effectiveness of
SBT using a daily boost of external irradiation to inhibit
proliferation of tumor cells during the protracted
low-dose irradiation.17,18
Follow-up
Follow-up examinations were carried out as described
previously.9,10 In brief, clinical and neuroradiological
follow-up examinations were performed 3 months after
SBT and then at 6- to 12-month intervals.
The treatment response after SBT was estimated
similar to theRevisedAssessment inNeuro-Oncology cri-
teria19 at the time of the last follow-up or at the time of an
assumed tumor progression. In detail, we colocalized
follow-upMRIs with treatment planning data to colocal-
ize image changes with tumor extension prior to SBT and
dose distribution. Briefly, tumor size was determined by
the product of the 2 largest perpendicular diameters of
the T2 hyperintense lesion in non-enhancing tumors.
In tumors displaying contrast enhancement, response cri-
teriaconsideredboth the sizeof theT2hyperintense lesion
and any change of the enhanced T1-weighted images.
A complete disappearance of the lesion on MRI (contrast
enhanced T1-weighted images and T2-weighted images)
was defined as complete response; a tumor volume reduc-
tion.50% inboth non-enhancing and enhancing lesions
(compared with baseline) was considered a partial re-
sponse. A tumor volume increase .25% (T2-weighted
images or contrast enhanced T1-weighted images)
outside the volume enclosed by the therapeutic isodose
was defined as tumor progression, whereas a tumor
volume increase (T2-weighted images or contrast en-
hanced T1-weighted images) inside the therapeutic
isodose was defined as a breakdown of the blood–brain
barrier caused by SBT if these tumors did not progress
within 6 months after this finding. Otherwise, treatment
response was classified as tumor control (stable disease).
The biological significance of radiological susceptive
tumor progression was determined noninvasively by
PET imaging20,21 orcloseMRI follow-up,orbystereotac-
tic biopsy (or resection).
The patients’ functional outcomewas rated 12months
after SBTbyusing themodifiedRankin Scale.9,10,22 In ad-
dition, seizure frequency outcome was evaluated accord-
ing to Engel classification.23
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Statistical Analysis
Statistical analysis was performed using SPSS Statistics
20.0. Kaplan–Meier estimates were used to assess pro-
gression-free survival (PFS) and overall survival (OS).
Patients not experiencing progression were censored at
their last follow-up. The chi-square test was applied to
identify differences in baseline clinical and epidemiologi-
cal characteristics between the WHO grades II and III
glioma subgroups. Univariate analysis (log-rank test)
was performed to identify possible covariates with an in-
fluence on PFS. The following covariateswere included in
the analysis: sex,KPS (,90 vs≥90), tumor volume (≤ 10
vs .10 mL), WHO grade (II vs III), histology (astro-
cytoma vs oligoastrocytoma or oligodendroglioma), and
previous treatment (yes/no). In thenext step, factors iden-
tified as significant were included in a multivariate analy-
sis (Coxproportional hazardsmodel). The chi-square test
was used to identify predictive factors for patients devel-
oping radiation-induced cysts. P, .05 was considered
significant. In detail, the factors evaluated regarding the
occurrence of radiation-induced cysts were WHO grade,
tumor volume, number of implanted seeds/catheters,
and seed activity.
Results
Sixty consecutive patients (n ¼ 30 with WHO grade II
and n ¼ 30 withWHO grade III gliomas) fulfilled the se-
lection criteria of this study. Baseline epidemiological and
clinical parameters are outlined in Table 1. None of these
parameters differed significantly between the grade II and
grade III subgroups. Most of the patients (77%) received
SBT as primary treatment. For (re)evaluation of histology,
the majority of patients (92%, n ¼ 55) underwent stereo-
tactic biopsy and SBTwithin the same surgical procedure.
The remaining 5 patients (8%) received a combined proce-
dureofpartial tumor resectionandSBT,wherehistological
evaluation was performed at the time of surgery.
Irradiation Parameters
All patients receivedpermanent implantationof 125I seeds
with a median surface dose of 50 Gy (range, 50–65 Gy).
The median calculated coverage was 97.01% (mean,
96.03+3.83%; range, 79.77%–100.00%). The median
activity of the implanted seeds was 8.7+4.1 mCi (range,
3.0–26.9 mCi). On average we inserted 4.0 seeds (SD
2.0; range, 1–10) and 1.8 catheters (SD 0.8; range, 1–3)
in order to use as few catheters as possible. Following our
protocol, 29 of 30 patients with WHO grade III gliomas
received concurrent percutaneous radiotherapy (median
boost dose, 25.2 Gy; range, 21.6–30.6 Gy, in fractions
of 1.8 Gy) within 3 weeks after SBT. One patient died
prior to scheduled percutaneous radiotherapy due to
rapidly developing erysipelas of the leg.
Oncological and Clinical Outcome
Outcome characteristics, including details of procedure-
related complications, radiological and neurological
outcomes, and salvage treatment procedures, are listed
in Table 2. Patients were followed for a median of 58
months (grade II gliomas) or 39 months (grade III).
Median PFS for grade II gliomas was 62.2+19.7
months; actuarial PFS rates were 93.3+4.6% (1 and 2 y)
and 52.5+10.6% (5 y). In contrast, patients with grade
III gliomas achieved a median PFS of 26.1+17.9 months;
actuarial PFS rates were 83.3+6.8%, 52.1+9.3%, and
34.2+9.6%at1, 2, and 5 years (Fig. 1). The correspond-
ing actuarial OS rates after 1, 2, and 5 years were
100.0+0.0%, 100.0+0.0%, and 94.7+5.1% for
grade II gliomas and 96.7+3.3%, 80.1+8.0%, and
59.4+10.9% for grade III gliomas (Fig. 2).
Procedure-related mortality was zero. Within 30 days
after SBT, 11 patients (18%) showed transient deteriora-
tion of clinical status and 1 patient (2%) showed perma-
nent deterioration of clinical status. Space-occupying
cysts occurred in 6 patients after a median of 38 months
(range, 12–97 mo) and required surgical intervention.
Following intervention, the neurological status improved
to baseline in 5 patients, while 1 patient remained un-
changed regarding his motor deficit. One grade III
glioma patient developed a symptomatic radiation necro-
sis 19months after SBT (50 Gy) + EBRTboost (25.2 Gy)
and required microsurgical intervention.
Neurological status improved or remained stable for
the majority of patients (83%). Worsening (17%) was
Table 1. Baseline epidemiological and clinical characteristics
Parameter Grade II
Gliomas
Grade III
Gliomas
Number of patients 30 30
Sex, n (%)
Female 10 (33) 10 (33)
Male 20 (67) 20 (67)
Age, y
Median (range) 36 (16–77) 42 (9–75)
KPS
Median (range) 90 (60–100) 90 (70–100)
Symptoms prior to SBT, n (%)
Seizures 25 (83) 25 (83)
Motor deficits 5 (17) 7 (23)
Sensory deficits 3 (10) 3 (10)
Speech disorder 2 (7) 2 (7)
Histology, n (%)
Astrocytoma 27 (90) 22 (73)
Oligoastrocytoma 1 (3) 5 (17)
Oligodendroglioma 2 (7) 3 (10)
Indication for SBT, n (%)
Primary treatment 23 (77) 23 (77)
Stand-alone 21 (70) 20 (67)
Combined with partial
Rx
2 (7) 3 (10)
Progression after Rx 7 (23) 7 (23)
Volume of tumor, mL
Median (range) 21 (3–50) 16 (8–56)
Abbreviation: Rx, resection.
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related to tumor progression (n ¼ 8), early postoperative
deterioration (n ¼ 1), and radiation-induced cysts (n ¼ 1).
These results were reflected by the modified Rankin Scale
displaying the patients’ functional outcomes (Fig. 3).
Seizure activity, rated 12 months following SBT, de-
creased in 82% of patients (Engel classes I–III).
Table 2. Details on procedural morbidity and radiological and neurological outcomes
Parameter Grade II Gliomas Grade III Gliomas
Radiological response at last follow-upA1
Complete remission, n (%) 1 (3) 0 (0)
Partial remission, n (%) 6 (20) 2 (7)
Stable disease, n (%) 9 (30) 8 (27)
Progressive disease, n (%) 14 (47) 20 (67)
Time to progression, mo Median 52.8+30.4 19.4+26.1
Range 6.6–113.4 4.4–88.7
Procedure-related morbidity
Early morbidity (30-day postop), n (%) 8 (27) 3 (10)
Transient 1 (3) 1 (3)
Motor deficits 0 (0) 1 (3)
Language deficits 7 (23) 1 (3)
Increased seizure activity 0 (0) 1 (3)
Permanent 0 (0) 1 (3)
Motor deficits 4 (13) 1 (3)
Delayed morbidity after SBT, n (%) 1 (3) 1 (3)
Due to radiation-induced cysts 3 (10) 0 (0)
Transient 1 (3) 0 (0)
Increased seizure activity 1 (3) 0 (0)
Motor deficits 0 (0) 1 (3)
Permanent 0 (0) 1 (3)
Motor deficits
Due to radiation necrosisA2
Transient
Increased seizure activity
Clinical outcome, rated 12 mo after SBT
Neurological outcomeA3,4 14 (47) 11 (38)
Improved 12 (40) 12 (40)
Stable 4 (13) 6 (20)
DeterioratedA5 12 (48) 11 (44)
Seizure outcome (Engel classification2)A6 4 (16) 4 (16)
I, free of disabling seizures 4 (16) 6 (24)
II, rare disabling seizures 5 (20) 4 (16)
III, meaningful seizure improvement
IV, no improvement or worseningA7
Salvage treatment after progression, n (%)
Microsurgery 9 (30) 4 (13)
Stand-alone tumor resectionA8 6 (20) 0 (0)
Combined with adjuvant RT and/or chemotherapyA9 3 (10) 3 (10)
Combined with SBT 0 (0) 1 (3)
RT and/or chemotherapy 3 (10) 10 (33)
SBT 1 (3) 2 (7)
Annotations: A1 ¼ estimated similar to the Revised Assessment in Neuro-Oncology criteria.19 A2 ¼ developed 19 mo after receiving SBT
(50 Gy) + EBRT boost (25.2 Gy) as primary treatment for grade III glioma. Followed for a period of 73 months, the patient is still alive;
follow-up MRI showed tumor control not requiring any further treatment. A3 ¼ rated in 59/60 patients. One patient (grade III subgroup)
died within the first month after SBT due to rapidly developing erysipelas (non-procedure-related mortality) and was therefore excluded from
this analysis. A4 ¼ including 5 patients with a follow-up period of,12 mo, where outcome was assessed at the latest follow-up. A5¼ due to
tumor progression (n ¼ 8), early postoperative deterioration (n ¼ 1), radiation-induced cysts (n ¼ 1). A6 ¼ rated in 50/60 patients; 10 patients
(5 each from the grade II and III subgroups) were excluded, as they did not show seizures. A7¼worsening was related to tumor progression
(n ¼ 4) or (transient) peritumoral edema (n ¼ 2); A8 ¼ (sub)total tumor resection in each case; postoperative hemiparesis reported for 3
patients; A9 ¼ partial tumor resection in each case.
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Prognostic Factors
Univariate analysis of covariates showed that neither
gender, age, KPS, previous treatment, treatment date,
nor treatment volumeproved to be statistically significant
forPFS.Thevariables of grade III andhistological diagno-
sis of “astrocytoma” were significantly associated with
reduced PFS (P ¼ .003 and P ¼ .015). On multivariate
analysis, both variables retained independent prognostic
significance. There was no association between the risk
for developing space-occupying cysts and the variables
of WHO grade, tumor volume, number of implanted
seeds/catheters, and seed activity.
Discussion
Herewepresent a unique series of 60patients treatedwith
SBT for grades II and III gliomas located in the CSR. We
focused on feasibility, procedural safety, and oncological
efficacy of SBT applied in a highly eloquent area of the
brain. SBT represents a strictly localized treatment
option for well-circumscribed tumors; its objective, as
well as that of microsurgical resection, is devitalization/
removal of the dense (visible) portion of tumor cells by
delivering a lethal irradiation dose (≥200 Gy in the vicin-
ity of the implanted source) from within the tumor while
optimally sparing the surrounding tissue. Thus, we com-
paredour treatment resultswith those reported formicro-
surgical resection.
The neurosurgical management of gliomas located in
eloquent brain remains a controversial issue for specific
reasons: (i) radical resection (complete or gross total)
seems to have an oncological impact1,2 but (ii) also
harbors a high risk for neurological disability, which in
turn may have a significant impact on the patient’s
further oncological treatment course. We therefore per-
formed a literature review to determine an accurate risk
profile for microsurgical tumor resection in eloquent
brain (focusingon tumors in theCSR). Eleven studies cov-
ering 943 patients were identified (Table 3). A gross total
resection was achieved in 61% of cases. The cumulative
overall risk for postoperative deficits was 32%, and in
9% of patients these were permanent. In the present
study, the 30-day postoperative morbidity was 20%.
Taking into account both early postoperative deteriora-
tion anddeteriorationover the long term, permanent neu-
rological deficits occurred in only 3% of our patients,
which is substantially lower than the reported incidence
from surgical groups (permanent neurological deficits in
9% of cases). These data clearly underline the safety of
SBT for gliomas in highly eloquent brain such as the
CSR and are in line with previous data on SBT for elo-
quent brain tumors.9,10,13,14 Besides its safety, strong in-
dicators for the efficacy of this treatment are oncological
outcome data (median PFS, 62 mo for grade II gliomas,
26 mo for grade III gliomas), as well as clinical outcome
data (improvement or stabilization of the neurological
status in 83% of patients, decreased seizure activity in
82%) (Fig. 4).
Is There a Place for SBT in the Management
of Grade II Gliomas?
According to the guidelines from the European
Federation of Neurological Societies and the European
Association ofNeuro-Oncology, surgical resection repre-
sents the first treatment option for grade II gliomas, with
the goal ofmaximally resecting the tumormasswhenever
possible while minimizing postoperative morbidity.24
When surgery is not feasible due to the location in
Fig. 2. Kaplan–Meier estimates for overall survival.
Fig. 1. Kaplan–Meier estimates for progression-free survival.
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eloquent brain, a biopsy should be performed to obtain
histological proof of malignancy. For these patients, as
well as thosewith incompletely resected tumors, adjuvant
treatment is indicated, usually in the form of EBRT.
Based on these guidelines, a subpopulation of patients
can be identified: those with tumors located in eloquent
brain receiving incomplete tumor resection or biopsy fol-
lowed by postoperative EBRT. However, the following
points should be consideredwhen applying this treatment
regimen in this specific subgroup:
1. Surgery is a critical therapeutic modality for patients
with grade II gliomas, where the extent of tumor re-
section is a strong prognostic factor, determining the
patient’s oncological outcome.1 Today, the aim of
surgeryshouldbecomplete resectionof thepreoperative
T2/fluid attenuated inversion recovery signal abnor-
malitywhile simultaneously avoiding operation-related
neurological deficits in order to improve survival and
quality of life. However, particularly those patients
with tumors located in eloquent brain (eg, the CSR)
should undergo critical preoperative evaluation, since
theyareathigh risk forboth incomplete tumor resection
and postoperative neurological deficits. This is under-
lined by our literature review (Table 3), revealing that
only 61% of tumors located in eloquent areas are ame-
nable to complete resection and that postoperative neu-
rological deficits occur in 32% (transient) and 9%
(permanent)of cases. SBT, aswell as surgery, is a strictly
local treatment regimen that has been shown tobe asso-
ciatedwithonlyminimal postoperativemorbidity, even
for tumors located in highly eloquent brain.9,10,13
Furthermore, from an oncological point of view, SBT
hasbeen reported tobe as effective as surgery in patients
with grade II gliomas.11,25Kreth et al11 compared grade
II patients receiving either SBT (n ¼ 239) or microsur-
gery (n ¼ 108) as primary treatment. The authors
observed no difference in terms of PFS or time tomalig-
nant transformation between the 2 treatment groups.
Moreover, a comparison of survival curves after SBT
(n ¼ 239) with those of surgery+ EBRT (n ¼ 150
from the European Organisation for Research and
Treatment of Cancer [EORTC] study 2284426) in pa-
tients with grade II gliomas showed nearly identical
results.11,26 The results from our present study
(median PFS, 62mo) comparewell with those reported
for grade II gliomas treated with surgery+ EBRT (eg,
median PFS in the EORTC 22844 and 22845 trials:
60 and 64 mo, respectively, for surgery+ EBRT27,28).
Interestingly, the reported median PFS of 41 months in
the EORTC 22845 trial for patients undergoing
surgery without EBRT is far below the median PFS in
our study (62 mo). However, whether the improved
PFS inour studywasbasedsimplyonfavorable selection
criteria for SBT (ie, its limitation forwell-circumscribed
tumors ≤4 cm in diameter) or by the treatment itself
remains to be determined in future studies.
Despite its efficacy and safety, the application of
SBT is, however, limited to well-circumscribed tumors
≤4 cm,since tumorsbeyondthis thresholdposeasignif-
icantly increased risk for radiation-induced side
effects.29 In contrast, the extent of surgery is usually de-
termined and limited by the tumor location itself, with
joint goals of maximal tumor resection and preserving
the patient’s neurological function. Taking into account
limitationsofbothSBTandsurgery, aplannedcombined
approach using these treatment modalities (low-risk
partial tumor resection followed by SBT for the residual
tumor) seems logical for large tumors (.4 cm) located in
eloquent brain.This approachhas alreadybeen reported
as a feasible and safe treatment concept for patientswith
large, grade II gliomas located in eloquent areas.12,14,29
Inthepresentstudy,5/60patients (8%)weresuccessfully
treated with this combined concept.
Fig. 3. Improved functional outcome rated 12 mo following SBT using the modified Rankin Scale—0: no symptoms at all; 1: no significant
disability despite symptoms, able to carry out all usual activities; 2: slight disability, unable to carry out all previous activities but able to look
after own affairs without assistance; 3: moderate disability, requiring some help but able to walk without assistance; 4: moderate severe
disability, unable to walk without assistance and unable to attend to own bodily needs without assistance; 5: severe disability, bedridden,
incontinent, and requiring constant nursing care and attention; 6: dead. FU, follow-up.
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Table 3. Resection of gliomas located in the CSR, review of literature
Study N Histology Location GTR Postoperative Neurological Deficits Oncological Outcome
Cedzich et al36 99 55% gliomas, 19% angiomas/
cavernomas, 12%
metastases, 14% others
100% CSR 71% Postop: n.r.; permanent: 17%
(impairment of motor function)
n.r.
Duffau et al37 60 52% LGG, 22% HGG, 15%
metastases, 12% others
70% CSR, 23% perisylvian
(dominant), 7% deep-seated
51% Postop: 52%; permanent: 5% n.r.
Duffau et al4 6 100% LGG 100% CSR (100% primary
somatosensory area)
83% Transient: 100%; permanent: 0% n.r.
Duffau et al38 8 (SP) 100% LGG 100% CSR 25% Postop: 63%; permanent: 13%
(severe motor deficit after 3 mo)
n.r.
Duffau et al4 12 (SP) 100% LGG 100% CSR (67% primary
somatosensory area, 33% primary
motor area)
n.r. Postop: 100% (sensory loss: 67%/
central facial palsy: 25%/
hypophonia: 8%); permanent: 17%
(mild residual dysesthesias)
n.r.
Keles et al5 294 59% HGG, 41% LGG Rolandic (CSR) and perirolandic lesions
(within 2 cm of the rolandic cortex)
n.r. Postop: 20% (new motor deficit);
permanent: 5% (persistent motor
deficit after 3 mo)
n.r.
Carrabba et al39 146 60% LGG, 40% HGG 30% CSR; 70% also involving
language areas or pathways
65% Postop: 42% (new motor deficits);
permanent: 5% (new motor deficits
after 1 mo)
n.r.
Shinoura et al40 18 61% metastases, 33% gliomas,
6% others
100% CSR (primary motor area) 56% Postop: 50%; permanent: 6% n.r.
Gonza´lez-Darder
et al7
17 41% LGG, 41% HGG, 18%
metastases
41% CSR, 18% superior frontal gyrus,
12% frontal operculum, 29%
subcortical (60% in the corona
radiata; 40% in the insular white
matter)
47% Postop: 71% (new motor deficit);
permanent: 47% (persistent motor
deficit after 1 mo)
n.r.
Talacchi et al41 171 100% HGG 55% CSR, 45% insular 54% Postop: 24% (worsened motor
function); permanent: 8%
(worsened motor function after 4
mo)
n.r.
Krieg et al42 112 82% HGG, 18% LGG 34% CSR, 34% adjacent to the
corticospinal tract, 32%
frontodorsal (close to the anterior
part of the internal capsule)
69% Postop: 30% (new motor deficit);
permanent: 13% (new permanent
deterioration of motor function),
stratified by histology: LGG: 0%,
HGG: 14%; stratified by location:
precentral gyrus: 39%, postcentral
gyrus: 5%, frontal to precentral
gyrus: 5%, corticospinal tract: 8%
Mean PF-FU: 9.7 mo
Cumulative rates 943 61% (390/637) Postop: 32% (270/844); permanent:
9% (82/943)
This series (SBT) 60 50% LGG, 50% HGG 100% CSR n.a. Postop: 18% (11/60); permanent: 3%
(2/60)*
Median PFS: 62 mo (LGG),
26 mo (HGG)
Abbreviations: HGG, high-grade glioma; LGG, low-grade glioma; n.a., not applicable; n.r., not reported; PF-FU: progression-free follow-up; SP, data extracted/calculated from a subpopulation.
* ¼ permanent deterioration in one patient immediately postoperative, in the other patient due to radiation-induced cysts 38 mo after SBT.
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2. Given the long course of the disease, with more than
one third of grade II glioma patients surviving at
least 10 years,30 timing and application of EBRT
need tobeplannedcarefully, since there is a substantial
riskof acquiring lateordelayed radiation injuries.This
is underlined by a recent study by Douw et al,31 who
evaluated the cognitive abnormalities in survivors of
grade II gliomas at a mean of 12 years after first diag-
nosis. They reported that deterioration of cognitive
function in patients receiving EBRT was twice as
high compared with those who were EBRT naive
(53% vs 27%). The authors recommended that defer-
ring EBRT might be the strategy most beneficial to
cognitive status and quality of life. We therefore
suggest that patients with grade II gliomas located in
eloquent brain be considered as candidates for SBT
instead of receiving incomplete tumor resection/
biopsy followed by upfront EBRT. Although struc-
tures involved inmemoryand cognition (eg, thehippo-
campus) are less likely to be exposed to EBRT for
gliomas located in the CSR, the occurrence of late or
delayed radiation injuries for brain tumors in general
seems—despite only limited available data9,10—less
likely for SBT comparedwith EBRT. Since the irradia-
tion source is directly placed into the tumors, this
results inaverysteepdose fall-off toward theperiphery
Fig. 4. T2-weighted images of a 36-year-old neurologically intact female patient presenting in 2002 with secondary generalized motor seizures,
showing a non–contrast enhancing tumor involving the precentral gyrus. A stereotactic biopsy revealed an astrocytoma of WHO grade II. (B)
After outlining the outer boundary of the visible tumor (yellow dotted line), one catheter containing 3 iodine-125 seeds (red line) was inserted
using aprecentral stereotactic approach.Thegreen line represents the therapeutic isodose (50 Gy,permanent implantation, coverage 98.7%). In
the following 3 months, she suffered an increased frequency of focal motoric seizures, which could then be controlled with anticonvulsive
medication. (C) Two years later, MRI showed partial response of the visible tumor on T2-weighted images and the typical temporary blood–
brain barrier breakdown resulting in contrast enhancement in the T1-weighted images. (D) In June 2013, the patient was without any
neurological deficit, was free from seizures, and showed complete remission of the tumor.
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within amillimeter range,which substantially reduces
the radiation burden on surrounding tissue.7,8
Therefore, late or delayed radiation injuries may be
avoided for those patients receiving SBT. It further-
more allows deferring EBRT until the time of tumor
progression, since previous SBT does not limit or
hinder the application of EBRT.8,9,12,14
Is There a Place for SBT in the Management
of Grade III Gliomas?
According to the German Neuro-oncology Working
GroupNOA-04 trial, the standard of care for newly diag-
nosed grade III gliomas is surgery followed by EBRT or
chemotherapy.32 This phase III study showed no diffe-
rence between the 2 treatment arms (postoperative
EBRT vs postoperative chemotherapy) regarding PFS
(median PFS, 30.6 mo for EBRT and 31.9 mo for chemo-
therapy) or OS (4-y OS, 72.6% for EBRT and 64.6% for
chemotherapy). In comparison with the NOA-04 trial,
our treatment (SBT + EBRT boost) achieved similar
results, with a median PFS of 26.2 months and a 4-year
OS rate of 71.2%. Although no definitive conclusion
can be drawn from this comparison—since different
patient selection criteria, aswell as adifferent distribution
of prognostic relevant factors (eg, mutation status of iso-
citrate dehydrogenase 1,33 which was not assessed in the
present study), may have influenced the oncological
outcome—we could, however, show that a combined
treatment with SBT + EBRT boost is a safe and effective
treatment option for highly eloquent grade III gliomas
not amenable to (a low-risk) complete tumor resection.
Furthermore, the oncological outcome in the present
study has to be seen in the context that in the NOA-04
trial, incomplete tumor resection and biopsy were—
compared with complete resection—associated with a
significantly increased risk for treatment failure (1.6 and
3.5 times [hazard ratios]).
In comparison with previous studies on SBT for grade
III gliomas, applying a combined treatment concept of
SBT + EBRTboost, the risk for development of radiation
necrosis in our study was substantially lower (1/30 [3%]
grade III patients compared with 19% in a study by
Fernandez et al17). Although the basic treatment concepts
(low-dose SBT + EBRT boost) were identical, other
groups applied cumulative SBT doses of more than
100 Gy followed by an EBRT boost of up to 50 Gy.17 In
contrast, we reduced irradiation to a cumulative SBT
dose of 50 Gy followed by an EBRT boost of 25 Gy.
The rationale for this treatment protocol was to decrease
the risk for radiation necrosis while simultaneously pre-
serving the oncological efficacy.34
Based on the results from the present study, we were
able to demonstrate that SBT in combination with an
EBRT boost is safe and efficient for treating inoperable
grade III gliomaswithin eloquent brain. The combination
of 2 irradiation modalities (SBT + EBRT) was originally
introduced to improve local tumor control rates for pa-
tients with grade III gliomas.17 However, validation of
this hypothesis is still pending, since convincing data
(from prospective, randomized trials) are still not avail-
able. Therefore, the place of SBT (in combination with
EBRT boost) within a multimodal treatment concept for
grade III gliomas is still unclear and remains to be deter-
mined in future studies.
Conclusions
The application of SBT in patients with tumors located
in highly eloquent brain, such as the CSR, is safe and—
compared with surgery—associated with only minimal
postoperative morbidity. The oncological efficacy of
SBT for patients with grade II gliomas seems to be at
least equal to surgery+EBRT. In addition, the applica-
tion of SBT as a primary treatment for grade II gliomas
allows deferring EBRT until the time of progression in
those patients whose tumors in eloquent brain would
likely have been treated with incomplete tumor resection
or biopsy followed by EBRT. Hence, late or delayed radi-
ation injuries from EBRT can be avoided. Oncological
outcomes of grade III glioma patients receiving a combi-
nation of SBT followed by EBRT boost were promising
and comparable to those from the NOA-04 trial.
However, the value of this treatment concept remains to
be determined in future studies.
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